Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …

EpCAM (epithelial cell adhesion molecule) was discovered four decades ago as a tumor
antigen on colorectal carcinomas. Owing to its frequent and high expression on carcinomas …

Cancer is the second most common cause of death in the United States, trailing only heart
disease in incidence. Despite significant worldwide investment in research, cancer remains …

Patients undergoing surgical resection of primary breast tumors confront a risk for metastatic
recurrence that peaks sharply 12 to 18 months after surgery. The cause of early metastatic …

Metastatic spread of tumour cells is the main cause of cancer-related deaths. Understanding
the mechanisms of tumour-cell dissemination has, therefore, become an important focus for …

Circulating tumor cells, a component of the “liquid biopsy”, hold great potential to transform
the current landscape of cancer therapy. A key challenge to unlocking the clinical utility of …

Recent pre-clinical and clinical research has provided evidence that cancer progression is
driven not only by a tumour's underlying genetic alterations and paracrine interactions within …

The fundamental operative unit of a cancer is the genetically and epigenetically innovative
single cell. Whether proliferating or quiescent, in the primary tumour mass or disseminated …

Background The management of metastatic breast cancer requires monitoring of the tumor
burden to determine the response to treatment, and improved biomarkers are needed …